DRUG

Peers: STOK XENE PRAX RAPP OVID SPTX HELP GHRS MPLT NMRA

| Held by: IWM VTWO IWO FESM PSIL IWC VTWG GWX AVSC GSSC

Index	RUT
Market Cap	236.39M
Enterprise Value	19.47M
Income	-17.75M
Sales	0.00M
Book/sh	21.99
Cash/sh	22.00
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	25
IPO	Mar 22, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.09
P/C	1.09
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	121.97
Current Ratio	121.97
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-2.08
EPS next Y	-6.12
EPS next Q	-1.16
EPS this Y	-108.64%
EPS next Y	-125.12%
EPS next 5Y	-
EPS past 3/5Y	35.51% -35.46%
Sales past 3/5Y	- -
EPS Y/Y TTM	-120.28%
Sales Y/Y TTM	-
EPS Q/Q	67.03%
Sales Q/Q	-
Earnings	Aug 17 BMO
EPS/Sales Surpr.	86.51% -

Insider Own	23.39%
Insider Trans	0.00%
Inst Own	83.38%
Inst Trans	2.53%
ROA	-13.80%
ROE	-13.93%
ROIC	-8.18%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-45.45%
SMA50	-54.53%
SMA200	-66.40%
Trades

Shs Outstand	9.86M
Shs Float	7.56M
Short Float	10.98%
Short Ratio	4.71
Short Interest	0.83M
52W High	123.75 -80.63%
52W Low	17.40 37.73%
Volatility	28.40% 12.13%
ATR (14)	5.09
RSI (14)	27.70
Beta	-4.57
Rel Volume	0.39
Avg Volume	176.04K
Volume	44,732

Perf Week	-8.53%
Perf Month	-55.66%
Perf Quarter	-70.14%
Perf Half Y	-72.31%
Perf YTD	-69.29%
Perf Year	-59.24%
Perf 3Y	1817.20%
Perf 5Y	-39.33%
Perf 10Y	-
Recom	1.11
Target Price	120.95
Prev Close	23.00
Price	23.97
Change %	4.20%

Consensus

Strong Buy

Avg. Price Target

$120.95

Implied Upside

+404.7%

Analysts9incl. previous ratings

Rating Distribution9 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 15, 2026	Initiated	WWolfe Research	Outperform	$150	+525.9%
Apr 13, 2026	Initiated	JJefferies	Buy	$145	+505.0%
Sep 08, 2025	Initiated	BBTIG Research	Buy	$72	+200.4%
May 13, 2025	Initiated	TTD Cowen	Buy
May 07, 2025	Initiated	CChardan Capital Markets	Buy	$80	+233.8%
Jan 23, 2025	Initiated	PPiper Sandler	Overweight	$93	+288.1%
Jan 10, 2025	Initiated	HH.C. Wainwright	Buy	$85	+254.7%
Jan 10, 2025	Initiated	CCantor Fitzgerald	Overweight
Nov 26, 2024	Initiated	RRobert W. Baird	Outperform	$75	+213.0%

Nov-08-26 03:56PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Nov-03-26 07:41AM	FDA puts partial hold on Bright Minds Phase II seizure study (Clinical Trials Arena) -17.75%
Nov-02-26 10:51AM	Bright Minds Biosciences Faces Partial FDA Clinical Hold on BMB-101 Phase 2 Epilepsy Study (InvestorsHub) -52.35%
10:02AM	Bright Minds stock plunges as FDA halts epilepsy trial (Investing.com)
07:30AM	Bright Minds Biosciences Provides Update About Planned Study with BMB-101 in Developmental and Epileptic Encephalopathies (GlobeNewswire)
05:30PM	Loading…
Sep-30-26 05:30PM	Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference (GlobeNewswire)
Sep-04-26 04:30PM	Bright Minds Biosciences to Present at Upcoming Conferences (GlobeNewswire)
Aug-28-26 12:31PM	What Makes Bright Minds Biosciences Inc. (DRUG) a Strong Momentum Stock: Buy Now? (Quartz)
May-26-26 07:18PM	Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
Mar-06-26 10:15AM	Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results (TipRanks)
Feb-25-26 04:30PM	Bright Minds Biosciences to Present at Upcoming Conferences (GlobeNewswire) -5.00%
Feb-18-26 09:31PM	Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming Trials (Insider Monkey) +7.20%
Feb-17-26 10:09AM	Canadian Securities Exchange Reports January 2026 Performance Figures (TMX Newsfile) +7.72%
Jan-09-26 11:56AM	Bright Minds Biosciences Announces Closing of US$175 Million Public Offering (GlobeNewswire)
Jan-07-26 09:33PM	Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock (GlobeNewswire) -6.22%
04:00PM	Loading…
Jan-06-26 04:00PM	Bright Minds Biosciences Announces Launch of US$100 Million Public Offering (GlobeNewswire) +16.50%
07:16AM	Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE) (GlobeNewswire)
Jan-05-26 04:30PM	Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026 (GlobeNewswire)
Nov-26-25 08:55AM	Recent Price Trend in Bright Minds Biosciences Inc. (DRUG) is Your Friend, Here's Why (Zacks)
Nov-25-25 04:30PM	Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting (GlobeNewswire) +8.37%
09:55AM	Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 36.27%: Read This Before Placing a Bet (Zacks)
Nov-17-25 05:29PM	Why Bright Minds Biosciences Stock Topped the Market on Monday (Motley Fool)
06:50AM	Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS) (GlobeNewswire)
Nov-06-25 06:30AM	Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH (GlobeNewswire) +7.55%
Oct-30-25 06:30PM	Bright Minds Biosciences to Present at Upcoming Conferences (GlobeNewswire)
Oct-15-25 08:50AM	Bright Minds Biosciences Inc. (DRUG) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Sep-18-25 09:55AM	Wall Street Analysts Believe Bright Minds Biosciences Inc. (DRUG) Could Rally 81.29%: Here's is How to Trade (Zacks) +12.23%
Sep-07-25 05:29PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Sep-04-25 08:30AM	Bright Minds Biosciences Announces BMB-201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model (GlobeNewswire)
Sep-02-25 09:55AM	Does Bright Minds Biosciences Inc. (DRUG) Have the Potential to Rally 114.07% as Wall Street Analysts Expect? (Zacks)
03:50AM	Loading…
03:50AM	Bright Minds Biosciences Inc. (DRUG) Advances Phase 2 Trial for Drug-Resistant Epilepsy (Insider Monkey)
Aug-25-25 08:00AM	Bright Minds Biosciences to Present at Upcoming Conferences (GlobeNewswire) -5.14%
May-28-25 08:00AM	Bright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference (GlobeNewswire)
May-20-25 08:00AM	Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025 (GlobeNewswire)
May-13-25 08:30AM	Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101 (GlobeNewswire)
May-11-25 03:33PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
May-09-25 11:11AM	Psychedelic: Compass, GH Research, MindMed report quarterly earnings (TipRanks)
Apr-28-25 08:00AM	Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study (GlobeNewswire)
Apr-16-25 12:09PM	Bright Minds Biosciences: A Buy With A Major Catalyst In Q2 2025 (Seeking Alpha)
Mar-04-25 08:00AM	Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research (GlobeNewswire) -7.70%
Feb-24-25 06:50AM	Bright Minds Biosciences to Participate at Three Healthcare Conferences in March (GlobeNewswire)
Jan-07-25 06:50AM	Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer (GlobeNewswire)
Nov-21-24 09:00AM	Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting (GlobeNewswire)
Nov-06-24 06:30AM	Bright Minds Biosciences Secures $35 Million Investment (TipRanks)
Nov-04-24 02:41PM	Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement (GlobeNewswire) +5.00%
Oct-21-24 08:30AM	Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data (GlobeNewswire)
Oct-18-24 06:50AM	Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement (GlobeNewswire) +117.56%
Oct-16-24 10:45AM	Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models (GlobeNewswire) -25.18%
09:20AM	Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA Technology (GlobeNewswire)
05:57AM	Biotech stock tumbles after unexplained 1,446% gain (MarketWatch)
Oct-15-24 09:09PM	Bright Minds is Unaware of Any Material Changes (Newsfile) +1,445.78%
Oct-03-24 09:00AM	Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events (GlobeNewswire)
Sep-19-24 10:00AM	Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th (GlobeNewswire)
Sep-12-24 08:00AM	Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy (PR Newswire)
Aug-12-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
May-20-24 11:53AM	DRUG Stock Earnings: Bright Minds Biosciences Reported Results for Q2 2024 (InvestorPlace)
Dec-06-23 05:08PM	Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management (PR Newswire) +5.53%
Aug-08-23 06:50AM	Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101 (GlobeNewswire) +29.50%
Jul-20-23 06:50AM	Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101 (GlobeNewswire) -16.38%
Jul-11-23 06:50AM	Bright Minds Announces Effective Date of Share Consolidation (GlobeNewswire)
Jun-22-23 06:50AM	Bright Minds Announces Proposed Share Consolidation (GlobeNewswire) +5.33%
Apr-19-23 06:50AM	Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202 (GlobeNewswire) +26.08%
Apr-10-23 06:50AM	Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research (GlobeNewswire)
Feb-27-23 06:50AM	Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023 (GlobeNewswire) -10.54%
Feb-17-23 06:50AM	Bright Minds Biosciences Announces Non-Executive Director Appointment (GlobeNewswire)
Feb-08-23 04:05PM	Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements (GlobeNewswire) -6.58%
Jan-27-23 04:05PM	Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency (GlobeNewswire) -6.59%
Jan-09-23 04:05PM	Bright Minds Biosciences Announces Resignation of Board Member (GlobeNewswire) -7.46%
Dec-02-22 07:07PM	Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement (GlobeNewswire)
Nov-28-22 06:50AM	Bright Minds Biosciences Announces Non-Brokered Private Placement (GlobeNewswire) +10.78%
Nov-23-22 11:35AM	Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer (GlobeNewswire)
Sep-07-22 06:50AM	Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors (GlobeNewswire)
Aug-31-22 06:50AM	Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome (GlobeNewswire) -15.42%
Aug-30-22 03:35PM	Bright Minds Biosciences Announces Closing of $4 Million Unit Offering (GlobeNewswire) -23.05%
Aug-23-22 09:07PM	Bright Minds Announces Pricing of Overnight Marketed Offering of Units (GlobeNewswire) -38.43% +48.87%
Aug-22-22 07:05PM	Bright Minds Announces Overnight Marketed Offering of Units (GlobeNewswire) +72.80%
Aug-18-22 03:34PM	Bright Minds Biosciences Comments on Recent Trading Activity (GlobeNewswire) +121.43%
Jun-27-22 06:50AM	Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization (GlobeNewswire)
May-12-22 06:50AM	Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome (GlobeNewswire)
May-02-22 06:50AM	Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties (GlobeNewswire)
Apr-19-22 06:50AM	Bright Minds Biosciences to Host Symposium on Therapeutic Developments within Dravet Syndrome and Featuring a Panel with Key Opinion Leaders (GlobeNewswire) +8.40%
Mar-14-22 06:50AM	Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial (GlobeNewswire)
Mar-08-22 07:30AM	Bright Minds Biosciences to Present at the Oppenheimer 32nd Annual Healthcare Conference (GlobeNewswire)
Jan-04-22 04:05PM	Bright Minds Biosciences to Present at the H.C. Wainwright Bioconnect Conference (GlobeNewswire)
Dec-15-21 05:13PM	Canadian Securities Exchange's November 2021 Performance Includes Strong Listings Growth and New Financing Milestone (Newsfile) +5.88%
Dec-06-21 06:50AM	Bright Minds Biosciences to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference (GlobeNewswire)
Nov-30-21 07:30AM	Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases (GlobeNewswire) -8.35%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cormorant Asset Management, LP	Former 10% Owner	Apr 28 '26	Sale	89.50	109,331	9,785,124	950,000	Apr 30 04:07 PM

Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company was founded by Ian B. McDonald and Alan P. Kozikowski on May 31, 2019 and is headquartered in Chicago, IL.

Co-FounderMr. Ian McDonald

C.A.Mr. Ryan E. S. K. Cheung B.Com.

Ph.D.Dr. Jan Torleif Pedersen M.Sc.

COO & Senior Scientific OfficerMr. Alex Vasilkevich

Ph.D.Dr. Emer Leahy M.B.A.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Bright Minds Biosciences Inc

Upgrade your Finviz experience